Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5128]
News [14858]
Articles [105]
Editorials [3]
Conferences [245]
elearning [21]
Dual immunotherapy shows promise to treat recurrent or metastatic nasopharyngeal cancer
Dual immunotherapy shows promise to treat recurrent or metastatic nasopharyngeal cancer
ASCO 2023: Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced lung cancer
ASCO 2023: Real-world data suggests stopping immunotherapy after two years is reasonable in patients with advanced...
ASCO 2023: Antibody-microtubule inhibitor conjugate improves survival in women with recurrent ovarian cancer
ASCO 2023: Antibody-microtubule inhibitor conjugate improves survival in women with recurrent ovarian cancer
ASCO 2023: Vorasidenib delays disease progression or death in grade 2 glioma with IDH mutation
ASCO 2023: Vorasidenib delays disease progression or death in grade 2 glioma with IDH mutation
ASCO 2023: Phase 3 trial demonstrates one-year PFS in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy
ASCO 2023: Phase 3 trial demonstrates one-year PFS in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma...
ASCO 2023: Nivolumab reduces risk of disease progression or death in untreated hodgkin lymphoma compared to brentuximab
ASCO 2023: Nivolumab reduces risk of disease progression or death in untreated hodgkin lymphoma compared to...
ASCO 2023: Osimertinib after surgery significantly improves survival in patients with resected EGFR-mutated non-small cell lung cancer
ASCO 2023: Osimertinib after surgery significantly improves survival in patients with resected EGFR-mutated non...
ASCO 2023: For advanced, HER2-amplified bile duct cancers, antibody treatment trial shows promising results
ASCO 2023: For advanced, HER2-amplified bile duct cancers, antibody treatment trial shows promising results
Memory killer cells can improve survival for melanoma patients
Memory killer cells can improve survival for melanoma patients
ASCO 2023: Targeted therapy induces responses in HER2-amplified biliary tract cancer
ASCO 2023: Targeted therapy induces responses in HER2-amplified biliary tract cancer

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation